Optimizing adjuvant therapy: chemotherapy necessity in HR-positive breast cancer скачать в хорошем качестве

Optimizing adjuvant therapy: chemotherapy necessity in HR-positive breast cancer

Kevin M. Kalinsky, MD, Winship Cancer Institute in Atlanta, GA, discusses a crucial question for high-risk premenopausal women: the necessity of chemotherapy alongside ovarian function suppression with endocrine therapy. Dr Kalinsky highlights the ongoing Phase III OFSET (NCT05879926) trial, conducted by NRG, focusing on node-negative, hormone receptor (HR)-positive, HER2-negative breast cancer patients with specific recurrence scores. The trial aims to determine whether chemotherapy is essential in addition to endocrine therapy and ovarian function suppression. Dr Kalinsky emphasizes the evolving landscape of targeted therapies, such as CDK4/6 inhibitors, and optimizing adjuvant treatments, considering emerging agents that may provide additional benefits. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties globally. All rights are reserved.